Breaking News Instant updates and real-time market news.

CRME

Cardiome

$2.76

-0.03 (-1.08%)

, AGN

Allergan

$189.99

-2.23 (-1.16%)

08:02
11/29/16
11/29
08:02
11/29/16
08:02

Cardiome advances towards launching XYDALBA in the UK

Cardiome (CRME) is pleased to announce that it has moved one step closer to launching XYDALBA in the UK by receiving an established price from the Secretary of State for Health, under regulation 3 of the Health Service Branded Medicines Regulations. Commenting on the development, Hugues Sachot, Senior Vice President Commercial at Cardiome said, "We are extremely pleased with the progress that XYDALBA continues to make toward our imminent launch in the UK and other European countries we have under license from Allergan (AGN). The creation of an established price does not guarantee reimbursement in the UK, but it is a critical step in preparation for launch by allowing Cardiome to start negotiating with individual hospitals to gain formulary access for XYDALBA. Cardiome expects to make its first commercial sale in the UK before the end of 2016. We also continue to receive excellent feedback from our other countries as we prepare to offer physicians access to this unique dosage regimen that provides a new treatment approach giving patients, healthcare professionals and hospitals greater flexibility in managing serious skin infections."

CRME

Cardiome

$2.76

-0.03 (-1.08%)

AGN

Allergan

$189.99

-2.23 (-1.16%)

  • 29

    Nov

CRME Cardiome
$2.76

-0.03 (-1.08%)

03/11/16
ADAM
03/11/16
NO CHANGE
Target $10
ADAM
Buy
Cardiome price target lowered to $10 from $16 at Canaccord
Canaccord lowered its price target on Cardiome to $10 from $16 following Q4 results. The firm cited its weak results, lowered guidance for the peak potential for Brinavess in Europe, and significant hurdles that remain for the U.S approval for Brinavess. Canaccord maintained its Buy rating on Cardiome shares.
06/01/16
HCWC
06/01/16
INITIATION
Target $9.5
HCWC
Buy
Cardiome initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Cardiome Pharma with a Buy rating and $9.50 price target.
08/02/16
ADAM
08/02/16
NO CHANGE
Target $9
ADAM
Speculative Buy
Cardiome price target lowered to $9 from $13.75 at Canaccord
Canaccord lowered its price target on Cardiome to $9 from $13.75 following its secondary offering of shares at a "big discount" to the previous closing of the stock. The firm believes the discount has presented a buying opportunity, as the recent licensing deal for Xydalba accelerates the company's transformation into a European hospital-focused specialty pharmaceuticals company. Canaccord reiterated its Speculative Buy rating on Cardiome shares.
AGN Allergan
$189.99

-2.23 (-1.16%)

11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.

TODAY'S FREE FLY STORIES

UBS

UBS

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Periodicals
UBS to start moving jobs in early 2018 ahead of Brexit, Telegraph reports »

UBS will begin shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

PHM

PulteGroup

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

RF

Regions Financial

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Options
Overnight activity included 111 trades in SPX and 29 trades in VIX »

111 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

SDR

SandRidge Mississippian Trust II

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Hot Stocks
SandRidge Mississippian Trust II receives NYSE notice on listing standards »

SandRidge Mississippian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
01/22/18
01/22
09:15
01/22/18
09:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HAL

Halliburton

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
Halliburton says expects improved utilization to drive margin growth »

Sees boosting frack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
FirstEnergy receives $2.5B equity investment »

FirstEnergy announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DNKN

Dunkin' Brands

$64.56

-0.53 (-0.81%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Upgrade
Dunkin' Brands rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.85

-0.54 (-0.41%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Recommendations
Visteon analyst commentary  »

Visteon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.75

0.65 (1.00%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Conference/Events
Mellanox management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

IOVA

Iovance Biotherapeutics

$10.70

1.075 (11.17%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Recommendations
Iovance Biotherapeutics analyst commentary  »

Iovance Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:11
01/22/18
01/22
09:11
01/22/18
09:11
Hot Stocks
Halliburton says International business started to recover in 2H17 »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

09:10
01/22/18
01/22
09:10
01/22/18
09:10
General news
Treasury Option Action: doubly bullish positioning »

Treasury Option Action:…

GRA

W.R. Grace

$73.71

0.92 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Hot Stocks
W.R. Grace licenses UNIPOL PP process technology to Poland's Grupa Azoty »

W. R. Grace has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 02

    Mar

PRI

Primerica

$104.50

1.3 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Recommendations
Primerica analyst commentary  »

Primerica price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

ARCT

Arcturus Therapeutics

$9.15

-0.15 (-1.61%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Initiation
Arcturus Therapeutics initiated  »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$52.15

0.45 (0.87%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Upgrade
Meritage Homes rating change  »

Meritage Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

INSG

Inseego

$1.66

-0.01 (-0.60%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Hot Stocks
Inseego says board adopts NOL rights plan »

Inseego Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

XRX

Xerox

$31.80

0.43 (1.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Icahn, Deason call on Xerox to explore strategic alternatives, replace CEO »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:05
01/22/18
01/22
09:05
01/22/18
09:05
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.